Navigation Links
Safety and Efficacy of OrbusNeich's Genous™ Stent Demonstrated in High-Risk Patients with Known Contraindications for Dual Antiplatelet Therapy
Date:1/10/2011

d that the Genous Stent, which accelerates the natural healing process, enables a shorter post-procedural period of DAPT without increasing the risk of late or very late stent thrombosis and without causing dangerous delays for patients who require non-cardiac surgery shortly after PCI."

The single-center study investigated 61 high-risk patients with a clear contraindication to prolonged DAPT. A high-risk condition was defined as meeting at least two of the following criteria: diabetes, acute coronary syndrome, heart failure, proximal vessel disease, multivessel disease, B2/C type lesions, bifurcating lesions and long lesions.  The study's primary outcome measures were the occurrences of death, MI, target vessel revascularization (TVR), target lesion revascularization (TLR) and MACE, defined as a non-hierarchical composite of all cause death, nonfatal MI or repeat revascularization.

"This study adds to the growing body of knowledge published in peer-reviewed biomedical publications that supports the use of Genous for the treatment of challenging coronary indications," said Stephen M. Rowland, Ph.D., vice president of research and development at OrbusNeich. "We see in this case that high-risk patients with confounding co-morbidities precluding the use of DES still have an option that is safe and effective in the long-term."

About Genous

Genous is OrbusNeich's patented endothelial progenitor cell (EPC) capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

The Genous Stent, which  has been commercially available in more than 60 countries since 2005, has been proven as a safe, effective alternative to drug-eluting ste
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
4. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
5. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
6. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
7. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
8. Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
9. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
10. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... Taskforce representing Canada,s living victims of ... the Minister and Health Canada have put into this program ... of the thalidomide survivors, and more than 70% of them ... annual adjustments for inflation. Certain of the thalidomide ... on the severity of their disability, tax free, with inflation ...
(Date:5/22/2015)... HILL, N.C. , May 22, 2015 /PRNewswire/ ... critical to pharmaceutical brand recognition and success. ... LLC conducted a study to provide pharmaceutical and ... of investment (FTEs and budget) that are being ... Pharmaceutical and biotech marketing managers can utilize this ...
(Date:5/22/2015)... , May 22, 2015 The leading ... $13 billion global cardiac rhythm management device market ... found that Medtronic, St. Jude Medical, Boston Scientific ... of this market segment. The healthcare market research ... , uses 2015 as a base year, providing ...
Breaking Medicine Technology:Effective Marketing Services Group Critical for Pharmaceutical Brand Recognition 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 3Kalorama: Top Companies Dominate Cardiac Defibrillator Market 4
(Date:5/23/2015)... 23, 2015 A live auction will be ... hospitals, surgery centers and other medical facilities around the United ... endoscopy, lab, radiology, surgery, anesthesia, exam and much more. ... and Thursday, May 28 starting at 9:00am CDT each day. ... N. 25th Avenue, Melrose Park, IL 60160. Anyone can ...
(Date:5/22/2015)... Pioneer Millworks, the largest reclaimed wood company ... with reclaimed wood, introducing their latest reclaimed wood products ... newest offerings, Vat 35, Reclaimed Teak , and ... America's largest design event. , “Designers, architects, builders, and ... to see and feel the variety of wood surfaces ...
(Date:5/22/2015)... 22, 2015 Following yesterday’s announcement that ... with US-based health brand Nature’s Way, Marc St-Onge has ... of Ascenta Skin is an integral part of the ... this opportunity to further develop Ascenta Skin into a ... Skin is a breakthrough, anti-aging skincare supplement featuring 6 ...
(Date:5/22/2015)... Family, friends, students, colleagues, mentors and fellow physicians ... D. Leffall, on Monday, May 18, with an 85th ... in the hospital’s Tower Auditorium. Leffall’s younger sister, 83-year-old ... to keep the secret. “I’d like to go in ... know something is up,” she said. , After more ...
(Date:5/22/2015)... Power Systems is proud to announce the sponsorship of ... is in his second year of racing in the professional ... Fire Department in Missoula, MT. He entered the triathlon scene ... career, he has had 15 1st Place finishes. In his ... in all seven of his 2014 races, including two 2nd ...
Breaking Medicine News(10 mins):Health News:Over 5,200 Lots of Medical Equipment Will Be Sold by Live Auction 2Health News:Pioneer Millworks to Reveal New Design Trends with Reclaimed Wood at Dwell on Design in LA 2Health News:Pioneer Millworks to Reveal New Design Trends with Reclaimed Wood at Dwell on Design in LA 3Health News:Ascenta Skin President Announces Plans to Grow Brand 2Health News:Colleagues Surprise Dr. LaSalle Leffall with 85th Birthday Celebration 2
... , Appointments may be made at H1N1inPA.com or by phone ... offer H1N1 flu vaccination clinics at 33 locations across Pennsylvania on ... is urged to make an appointment to attend. , "We ... wants it," said Health Secretary Everette James. "Even though flu activity ...
... whose moms took low doses , TUESDAY, Dec. 22 ... low-dose aspirin during pregnancy because they are at high ... at age 5, new research suggests. , Obstetricians sometimes ... to have such complications as fetal growth restriction (when ...
... Victoria and her European relatives, scientific detectives used a cutting-edge ... mutations, the tool can turn a single laboratory into a ... its own deep sequencer one of the first in ... Facility. The tool will add an important new capability ...
... , , Rally to Call on ... 22 Today, Tuesday, December 22, 2009 at Noon, Family ... front of Senator Mary Landrieu,s office in downtown Baton Rouge. ... asking her to reconsider her support for President Obama,s health ...
... Ohio, Dec. 22 AdCare Health Systems, Inc. (NYSE Amex: ... management company today reported that the warrants issued in connection with ... of the new warrants that were included in the Company,s recent ... current growth initiatives. , On December 21, 2009, the ...
... be used for artificial blood vessels in the future as ... synthetic materials currently used for bypass operations, reveals a thesis ... Produced by a bacterium known as Acetobacter xylinum ... pressure and works well with the body,s own tissue. The ...
Cached Medicine News:Health News:Department of Health to Offer H1N1 Vaccine Clinics for All Pennsylvanians 2Health News:Aspirin During Pregnancy May Help Preemies 2Health News:Aspirin During Pregnancy May Help Preemies 3Health News:Adding a genetic supertool 2Health News:FRC's Tony Perkins to Address Rally Today at Senator Mary Landrieu's Senate Office 2Health News:AdCare Health Systems' Warrant Holders Approve Amending Terms of their Public Warrants 2
... The assay is a direct competitive ... in human serum or plasma. A specific ... it available for antibody binding. Estradiol then ... to fluorescein isothiocyanate (FITC) and alkaline phosphatase ...
... the most potent, naturally secreted estrogen and ... ovary [1]. In the ovary, estradiol is ... a less potent estrogen derived from androstenedione. ... body tissues. In men, small amounts of ...
... troponin I (cTnI) has been useful in ... Emergency Departments (ED) with chest pain. 18-20 ... when blood levels of sensitive and specific ... isoenzyme of creatine kinase (CK-MB), and myoglobin, ...
The second-generation Dade Behring Acute Care Troponin I (cTnI) method is the first FDA cleared high sensitivity cTnI assay with the low-end precision necessary to meet the ESC/ACC guidelines (CV <10...
Medicine Products: